Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease-Need More Evidence. Authors' Reply

被引：0
|
作者：
Zhao, Jianhui [1 ,2 ]
Xue, Erxu [3 ]
Liu, Zhanju [4 ]
Li, Xue [1 ,2 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Big Data Hlth Sci, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Sch Publ Hlth, Sch Med, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Sir Run Run Shaw Hosp, Nursing Dept, Sch Med, Hangzhou, Zhejiang, Peoples R China
[4] Tongji Univ, Shanghai Peoples Hosp 10, Ctr Inflammatory Bowel Dis Res, Sch Med,Dept Gastroenterol, Shanghai, Peoples R China
来源：
ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2024年 / 60卷 / 10期
基金：
中国国家自然科学基金;
关键词：
SURVIVAL ANALYSIS;
D O I：
10.1111/apt.18303
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1485 / 1486
页数：2
相关论文
共 50 条
  • [41] Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply
    Volkers, Adriaan
    Straatmijer, Tessa
    Duijvestein, Marjolijn
    Lowenberg, Mark
    van Der Meulen, Andrea
    D'Haens, Geert
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (06) : 743 - 744
  • [42] Letter: Light in the lumen-The expanding role of intestinal ultrasound for functional symptoms in inflammatory bowel disease. Authors' reply
    Mujagic, Zlatan
    Aliu, Arta
    Bosch, Daan H. C. A.
    Keszthelyi, Daniel
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 60 (06) : 835 - 836
  • [43] Letter: loss of response to anti-TNFα agents depends on treatment duration in patients with inflammatory bowel disease-authors' reply
    Mahmoud, Remi
    Schultheiss, Johannes P. D.
    Fidder, Herma H.
    Oldenburg, Bas
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (04) : 499 - 500
  • [44] Letter: impact of Epstein-Barr virus serological status on clinical outcomes in adult patients with inflammatory bowel disease - authors' reply
    de Francisco, Ruth
    Castano-Garcia, Andres
    Riestra, Sabino
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (04) : 477 - 478
  • [45] Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID-19 pandemic-authors' reply
    Hadi, Yousaf
    Kochhar, Gursimran S.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (01) : 178 - 178
  • [46] Letter: the safety of herpes zoster vaccination for patients with inflammatory bowel disease being treated with anti-TNF medications-authors' reply
    Khan, N.
    Lewis, J. D.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2018, 47 (03) : 448 - 448
  • [47] Letter: SARS-CoV-2 infection in two inflammatory bowel disease patients treated with dual targeted therapy-Authors' reply
    Al-Ani, Aysha H.
    Prentice, Ralley E.
    Rentsch, Clarissa
    Christensen, Britt
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (06) : 766 - 767
  • [48] Combination Therapy of Immunomodulators With Non-Anti-Tumor Necrosis Factor Agents in Inflammatory Bowel Disease: Need More Evidence?
    Pudipeddi, Aviv
    Paramsothy, Sudarshan
    Leong, Rupert W.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (03) : E640 - E641
  • [49] Letter: predicting treatment discontinuation in inflammatory bowel disease-anti-TNF trough levels and anti-drug antibodies. Authors' reply
    Roblin, Xavier
    Nancey, Stephane
    Paul, Stephane
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 54 (04) : 538 - 539
  • [50] Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axis-a unique therapeutic target in inflammatory bowel disease. Authors' reply
    Wang, Jie
    Goren, Idan
    Rieder, Florian
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (10) : 1360 - 1360
12345